Dr Zofia Piotrowska from the Massachusetts General Hospital in Boston discusses emerging strategies for patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.

CME information and select publications here.

Dr Mark Pegram from the Stanford University School of Medicine discusses the latest clinical data on and optimal use of newly approved therapies for HER2-positive metastatic breast cancer.

CME information and select publications here.

Dr Shaji Kumar from the Mayo Clinic in Rochester, Minnesota, and Dr Philip Thompson from the University of Texas MD Anderson Cancer Center discuss the role of minimal residual disease assessment in the management of multiple myeloma and chronic lymphocytic leukemia.

CME information and select publications here.

Dr Justin Gainor from the Massachusetts General Hospital in Boston discusses emerging targets in non-small cell lung cancer.

CME and select publications here.

Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville discusses the latest clinical data on and optimal management of ER-positive metastatic breast cancer.

CME and select publications here.

Dr Ann LaCasce from the Dana-Farber Cancer Institute discusses key presentations on chronic lymphocytic leukemia and follicular lymphoma from the 2020 ASH Annual Meeting.

CME information and select publications here.

Dr Kathleen Moore from the University of Oklahoma Health Sciences Center discusses key 2020 presentations on the role of PARP inhibitors and other treatment strategies in the management of advanced ovarian cancer.

CME information and select publications here.

Dr Steven Coutre from Stanford Medicine in California discusses recently published and emerging research in the front-line treatment of chronic lymphocytic leukemia. 

CME information and select publications here.

Dr Aaron Gerds from the Cleveland Clinic Taussig Cancer Institute discusses key presentations on myeloproliferative neoplasms from the 2020 ASH Annual Meeting.

CME information and select publications here.

Dr Matthew Galsky from the Icahn School of Medicine at Mount Sinai in New York discusses recently published and emerging data on newly approved agents for urothelial bladder carcinoma.

CME information and select publications here